CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: As shown in Fig. 2A, subsequent to a 24-h exposure to 1.0 μmol/l imatinib, the CD34+ cells from patients with CML in the megakaryocytic and myeloid crisis phases began to be arrested at the G1 phase.